Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RF16001 (ropivacaine sustained-release microspheres) for postoperative analgesia after total hip arthroplasty
CTR20253476Phase 2Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ropivacaine in postoperative pain (3 arms), sponsored by Yichang Humanwell Pharmaceutical Co., Ltd. Primary endpoint: Total morphine consumption 0–72 hours post-dose. Started Sep 2025; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20253476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253476.